EKF benefits from spin-out

EKF benefits from spin-out

EKF Diagnostics (EKF) may not pay a dividend, but shareholders didn't finish last year empty-handed. The company listed Renalytix AI – the developer of artificial intelligence-enabled diagnostics for kidney disease – on the Alternative Investment Market (Aim) in November, raising £22.3m. The nearly 21m shares owned by EKF were distributed to shareholders in October and currently have a value of approximately £29.3m. EKF also bought back £940,000-worth of its own shares during the year.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now